CA2412864C - Methodes de preparation et utilisation, et formulations pharmaceutiques renfermant 7.alpha.,11.beta.-dimethyl-17.beta.-hydroxyestra-4,14-dien-3-one et leurs 17-esters - Google Patents

Methodes de preparation et utilisation, et formulations pharmaceutiques renfermant 7.alpha.,11.beta.-dimethyl-17.beta.-hydroxyestra-4,14-dien-3-one et leurs 17-esters Download PDF

Info

Publication number
CA2412864C
CA2412864C CA2412864A CA2412864A CA2412864C CA 2412864 C CA2412864 C CA 2412864C CA 2412864 A CA2412864 A CA 2412864A CA 2412864 A CA2412864 A CA 2412864A CA 2412864 C CA2412864 C CA 2412864C
Authority
CA
Canada
Prior art keywords
beta
androgen
hydroxyestra
dien
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2412864A
Other languages
English (en)
Other versions
CA2412864A1 (fr
Inventor
Richard P. Blye
Hyun K. Kim
Carmie Kirk Acosta
Pemmaraju Narasimha Rao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Health and Human Services
Original Assignee
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2001/010293 external-priority patent/WO2001074839A2/fr
Application filed by United States Department of Health and Human Services filed Critical United States Department of Health and Human Services
Publication of CA2412864A1 publication Critical patent/CA2412864A1/fr
Priority claimed from PCT/US2002/009886 external-priority patent/WO2003045398A1/fr
Application granted granted Critical
Publication of CA2412864C publication Critical patent/CA2412864C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention concerne des procédés d'utilisation de 7 alpha ,11ss-diméthyl-17ss-hydroxyestra-4,14-dièn-3-one (III), de 7 alpha -méthyl-17ss hydroxyestra-4,14-dièn-3-one, et des esters en position 17 de ces composés destinés à diverses thérapies hormonales, des formes de dosage orale et parentérale contenant ces composés actifs, ainsi que leurs procédés de préparation.
CA2412864A 2000-03-31 2002-03-29 Methodes de preparation et utilisation, et formulations pharmaceutiques renfermant 7.alpha.,11.beta.-dimethyl-17.beta.-hydroxyestra-4,14-dien-3-one et leurs 17-esters Expired - Fee Related CA2412864C (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US19353000P 2000-03-31 2000-03-31
US60/193,530 2000-03-31
US19444000P 2000-04-04 2000-04-04
US60/194,440 2000-04-04
PCT/US2001/010293 WO2001074839A2 (fr) 2000-03-31 2001-03-30 Procedes de preparation et d'utilisation de7$g(a),11?-dimethyl-17?-hydroxy-4-estren-3-one 17?-$i(trans)-4-$i(n)-butylcyclohexane carboxylate et 7$g(a),11?-dimethyl-17?-hydroxyestr-4-en-3-one 17-undecanoate
WOPCT/US01/10293 2001-03-30
PCT/US2002/009886 WO2003045398A1 (fr) 2001-03-30 2002-03-29 Procedes de fabrication de formulations pharmaceutiques comprenant du 7alpha, 11beta-dimethy-17beta-hydroxyestra-4, 14-dien-3-one et des esters en position 17 de ce compose

Publications (2)

Publication Number Publication Date
CA2412864A1 CA2412864A1 (fr) 2002-03-29
CA2412864C true CA2412864C (fr) 2010-06-22

Family

ID=27359057

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2412864A Expired - Fee Related CA2412864C (fr) 2000-03-31 2002-03-29 Methodes de preparation et utilisation, et formulations pharmaceutiques renfermant 7.alpha.,11.beta.-dimethyl-17.beta.-hydroxyestra-4,14-dien-3-one et leurs 17-esters

Country Status (1)

Country Link
CA (1) CA2412864C (fr)

Also Published As

Publication number Publication date
CA2412864A1 (fr) 2002-03-29

Similar Documents

Publication Publication Date Title
US7196074B2 (en) Methods of making, using and pharmaceutical formulations comprising 7α, 11β-dimethyl-17β-hydroxyestra-4, 14-dien-3-one and 17 esters thereof
AU2001249661A1 (en) Methods of making the 4-n-butylcyclohexanoic and the undecanoic acid esters of (7 alpha, 11 beta)-dimethyl-17 beta-hydroxy-4-estren-3-one and their medical use
IE72193B1 (en) Steroids useful as anti-cancer anti-obesity anti-hyperglycemic anti-autoimmune and anti-hypercholesterolemic agents
KR100577129B1 (ko) 안드로겐 스테로이드 화합물 및 그의 제조 및 이용 방법
RU2216546C2 (ru) СОЕДИНЕНИЕ (7α,17β)-7-МЕТИЛ-17-[(1-ОКСОУНДЕЦИЛ)ОКСИ]ЭСТР-4-ЕН-3-ОН, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, НАБОР ДЛЯ МУЖСКОЙ КОНТРАЦЕПЦИИ
US10351587B2 (en) Method of making and using 7α, 11β-dimethyl-17β-hydroxyestr-4-en-3-one 17-undecanoate
MXPA01011227A (es) Glicosidas androgenas y su actividad androgenica.
US6677329B1 (en) Non-aromatic estrogenic steroids with a hydrocarbon substituent in position 11
CA2171740C (fr) Derives de 1,3,5(10)-estratriene, actifs par voie orale
EP1379253B1 (fr) Procedes de fabrication de formulations pharmaceutiques comprenant du 7alpha, 11beta-dimethy-17beta-hydroxyestra-4, 14-dien-3-one et des esters en position 17 de ce compose
AU2002258664B2 (en) Methods of making, using and pharmaceutical formulations comprising 7alpha, 11beta-dimethyl-17beta-hydroxyestra-4, 14-dien-3-one and 17-esters thereof
EP1212345A2 (fr) Androgenes actifs oralement
AU2006211907B2 (en) Nandrolone 17beta-carbonates
AU2002258664A1 (en) Methods of making, using and pharmaceutical formulations comprising 7alpha, 11beta-dimethyl-17beta-hydroxyestra-4, 14-dien-3-one and 17-esters thereof
EP1427748B1 (fr) Steroides 17alpha-hydroxy-14beta a effet hormonal
JP2007532688A (ja) １７α−フルオロ−１７β−ヒドロキシイミノメチルステロイド、それらを製造する方法および前記化合物を含んでなる医薬組成物
MXPA00012805A (en) Testosterone derivative
HK1063637B (en) 17alpha-hydroxy-14beta-steroids with hormonal effect

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20220301

MKLA Lapsed

Effective date: 20200831